trial
as of 2026-07-01A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
NCTId NCT07084831
at a glance
Phase 3 · Not Yet Recruiting
Enrollment 171 (estimated)
Sponsored by European Group for Research In Schizophrenia
Primary completion 2029-01-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Not Yet Recruiting
Enrollment
171 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2027-01-01
Primary completion
2029-01-01
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
European Group for Research In SchizophreniaLead Sponsor
Bristol-MyersCollaborator
University Medical Center GroningenCollaborator
Sites
16 total
Innsbruck, AustriaLeuven, BelgiumKlecany, CzechiaGlostrup Municipality, DenmarkAugsburg, GermanyCologne, GermanyMannheim, GermanyMünchen, GermanyBudapest, HungaryRamat Gan, IsraelNaples, ItalyTorino, Italy
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
171
Phase
PHASE3
Primary Completion Date
2029-01-01
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
lead_sponsor
collaborator
company
indication